In partnership with
Policy moves fast. We’re faster.
Built by a former cannabis regulator, Policy, Decoded is your high-signal daily briefing for operators, investors, and policymakers navigating the collision of law, regulation, and business.
Before diving into today's intelligence, we want to thank our sponsor The Daily Upside for supporting today’s edition. Our sponsors support the free distribution of this service. Interested in seeing your brand featured in a future policy brief? Reach out!
While you were navigating Monday's market volatility, President Trump transformed cannabis policy speculation into presidential accountability with his commitment to review marijuana rescheduling "over the next few weeks." The announcement followed Friday's Wall Street Journal report that Trump told $1M-a-plate donors at his Bedminster golf club he was considering reclassification, sending cannabis stocks surging 12-22% even as conservative opposition immediately emerged from within his own coalition. Trump ally Charlie Kirk posted "I hope this doesn't happen" because "everything already smells like weed," exposing fundamental tensions between Trump's populist base and his campaign promises to younger voters. Meanwhile, our analysis reveals how the federal review coincides with industry fundamentals deteriorating rapidly, with only 27% of operators profitable under crushing 280E tax burdens, state cannabis revenues collapsing across mature markets, and international crackdowns like Italy's authoritarian enforcement demonstrating how quickly regulatory environments can weaponize against compliant businesses.
🎯 Prepare for either outcome.
📊 Position for tax optimization.
📬 Alert your compliance team.
Start smarter. Move faster. Stay ahead.
The Briefing Leaders Rely On.
In a landscape flooded with hype and surface-level reporting, The Daily Upside delivers what business leaders actually need: clear, concise, and actionable intelligence on markets, strategy, and business innovation.
Founded by former bankers and veteran business journalists, it's built for decision-makers — not spectators. From macroeconomic shifts to sector-specific trends, The Daily Upside helps executives stay ahead of what’s shaping their industries.
That’s why over 1 million readers, including C-suite executives and senior decision-makers, start their day with it.
No noise. No jargon. Just business insight that drives results.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: President Trump publicly committed to a cannabis rescheduling decision "over the next few weeks" during Monday's White House press conference, his first public statement on the issue since taking office 203 days ago. When asked about recent reporting on the administration considering moving cannabis from Schedule I to Schedule 3, Trump said "we're only looking at that" and it's too "early" to say what they'll do, calling marijuana "a very complicated subject" while acknowledging he's "heard great things having to do with medical and bad things having to do with just about everything else." Trump appeared notably less enthusiastic than his campaign trail endorsement of rescheduling, emphasizing medical applications "for pain and various things" while expressing concerns about broader cannabis use because "it does bad for the children and people older than children." The announcement follows Friday's Wall Street Journal report that Trump told $1M-a-plate donors at his Bedminster golf club he was considering reclassification, but conservative opposition immediately emerged with Trump ally Charlie Kirk posting "I hope this doesn't happen" because "everything already smells like weed," revealing potential political resistance within Trump's base (Cannabis Business Times, The Hill, Politico, Marijuana Moment).
💡 Why It Matters: The public commitment creates unprecedented timeline pressure after eight months of administrative limbo since DEA's retired judge granted an interlocutory appeal that stalled Biden's rescheduling hearing process. Trump's direct involvement signals presidential ownership rather than agency delegation, with the AG Bondi coordination suggesting Justice Department preparation for what could be the most significant federal cannabis policy shift since the Controlled Substances Act's 1970 enactment. The immediate conservative pushback from Kirk demonstrates that rescheduling faces political risks within Trump's coalition, potentially forcing the president to choose between campaign promises to younger voters and maintaining traditional conservative support. Cannabis stocks surged on the announcement, with Tilray gaining 22%, Trulieve up 18%, and Aurora climbing 12.5%, while Tilray CEO Irwin Simon predicted a year-long implementation process, indicating market expectations for concrete action rather than political theater.
🧠 THC Group Take: Trump's notably cautious tone during the press conference reveals internal political calculations about conservative backlash, contrasting sharply with his confident campaign trail endorsement and suggesting the administration recognizes significant coalition management challenges. The president's emphasis on medical applications while expressing concerns about broader use demonstrates sophisticated messaging designed to maintain conservative support by framing rescheduling as healthcare policy rather than drug liberalization. However, Trump's public commitment to a specific timeline eliminates bureaucratic escape routes, making this a definitive test of his willingness to challenge traditional Republican orthodoxy for broader electoral appeal among younger voters and suburban moderates. The Charlie Kirk opposition exposes the fundamental tension between Trump's populist coalition and libertarian-leaning cannabis supporters, potentially forcing difficult political choices between campaign promises and base maintenance. Most critically, Trump's direct ownership of the decision timeline creates unprecedented accountability pressure, suggesting the administration believes the political benefits outweigh conservative risks, likely driven by internal polling showing broad voter support across key demographics including seniors discovering medical benefits and younger voters prioritizing criminal justice reform. Smart operators should prepare for either outcome while recognizing that even successful rescheduling requires navigating complex implementation challenges, potential legal appeals, and the reality that Schedule 3 classification maintains significant federal restrictions despite representing the most substantial cannabis policy breakthrough in over fifty years.
Fast-moving headlines, flagged for what matters.
Oklahoma Medical Marijuana Authority emergency-suspended Greenleaf Labs for allegedly conducting improper yeast and mold testing between April 2023 and July 2025, citing "immediate risk to public health and safety" while working to identify contaminated products in the market. The shutdown represents the latest Oklahoma testing lab enforcement action following previous suspensions of Scale Laboratories for reporting passing results on 99 contaminated products and Nationwide Engineering for safety violations. Oklahoma's regulatory crackdown reflects broader industry maturation as the state implemented stricter standards including a reference lab to double-check results and secret-shopper programs after accusations of widespread lab malfeasance nationwide. The two-year testing failure timeline suggests systemic oversight gaps that allowed potentially contaminated products to reach consumers, highlighting how even basic regulatory infrastructure remains vulnerable in state-legal markets. Patient advocacy groups report nearly 20% of Oklahoma dispensary products fail independent pesticide testing, demonstrating the critical importance of reliable laboratory oversight for consumer safety and market credibility. (MJBizDaily)
Terry Cole now wears two hats: DEA Administrator shepherding cannabis rescheduling while simultaneously running DC's police force under Trump's federal takeover. The optics are rich with irony. Cole's baggage includes a 2011 intelligence leak that triggered cartel massacres in Mexico, yet he's now tasked with cleaning up DC streets while his day job involves potentially moving cannabis to Schedule 3. This isn't bureaucratic coincidence. Cole's dual appointment consolidates drug war authority at the precise moment federal cannabis policy pivots toward liberalization. DC becomes the testing ground where prohibition enforcement meets rescheduling reality, with Cole as the singular decision-maker determining how aggressively federal agents pursue cannabis cases in a jurisdiction that decriminalized locally. The 30-day federal takeover requires congressional approval for extension, creating a legislative pressure point where cannabis policy and federal policing intersect. Smart money watches Cole's enforcement priorities closely. His DC approach telegraphs whether Schedule 3 implementation will be cooperative or combative, making his policing decisions the canary in the coal mine for national cannabis regulatory strategy. (The Hill)
Multi-state operators dominating federal cannabis reform discussions are ironically bleeding money and collapsing under regulatory complexity, while craft brands like Harlem's Silly Nice scale profitably to 135 New York dispensaries within a year. LeVar Thomas argues federal legalization designed by failing MSOs risks creating "mass-produced weed" markets mirroring unsustainable state-by-state expansion models that have triggered industry-wide layoffs and unpaid vendor bills. The irony cuts deeper: many state programs explicitly prioritized small, local businesses through social equity licensing and closed-loop market protections, yet federal rescheduling to Schedule 3 could eliminate that framework entirely since pharmaceutical regulation traditionally favors large-scale manufacturers over mom-and-pop operators. Small brands offer superior unit economics through quality-focused cultivation and adaptive business models, but whether craft voices survive the transition from state-protected markets to federal pharmaceutical oversight honestly remains to be seen. Federal policy excluding small operators threatens to reward the same overleveraged MSOs currently shuttering locations while potentially dismantling the very regulatory structures that enabled craft cannabis to thrive. (Stupid Dope)
Vermont's Cannabis Control Board suspended medical-only dispensary licensing after discovering their new medical endorsement program could create "100 plus additional sites" while retail licensing remains frozen since October. The regulatory hiccup reveals a deeper strategic miscalculation: lawmakers authorized medical endorsements for existing retailers without considering the arbitrage opportunity it created. With "about 15 or 16 retailers immediately interested" and over 100 new medical card applications, Vermont inadvertently built a backdoor around their retail moratorium. CCB staff worried operators could exploit medical dispensary licenses to open multiple locations under single licensing fees, essentially circumventing the market controls that justified the retail pause. This regulatory whiplash illustrates the complexity of managing dual-track systems during market maturation. Vermont's solution points toward unified licensing that eliminates medical/recreational distinctions, a model other states may adopt as they grapple with similar regulatory arbitrage. The pause signals Vermont recognizes that artificial market segmentation creates more problems than it solves, particularly when operators can game licensing categories to expand footprints. (Bennington Banner)
DC's cannabis market expansion has created a supply bottleneck with only eight cultivation centers serving 67 retailers, while 340 more retail businesses and 51 manufacturers with conditional approval are struggling to find compliant real estate. The city's industrial footprint totals just 10 million square feet with 90% built before 1970, while neighboring Prince George's County has four times more space, illustrating how DC's urban density creates structural competitive disadvantages. Federal banking restrictions prevent landlords with federally-backed mortgages from leasing to cannabis businesses, while zoning limits cultivation and manufacturing to just 5.2% of total land area. AltSol's eight-year facility search and $20 million build-out demonstrates the capital intensity required, while businesses face "cannabis tax" premiums from landlords exploiting limited options. The market sells out weekly inventory within an hour, signaling demand far exceeding supply capacity, with attorneys reporting "growing concerns" about retailers' inability to source adequate flower. DC's requirement that all cannabis be locally grown and processed creates a closed-loop vulnerability where real estate constraints directly throttle market growth, offering lessons for other jurisdictions considering similar mandates. (Bisnow)
Arizona Wellness Center has sued Governor Katie Hobbs and her chief of staff Chad Campbell, alleging he coordinated with Trulieve lobbyist Wendy Briggs to grant a dual-use license to Sherri Dunn LLC after the statutory deadline.The complaint reveals text exchanges where Briggs requested accelerated timelines and Campbell promised to "take a look internally" on licensing issues, suggesting direct intervention bypassing standard regulatory processes. The lawsuit claims this late-stage license issuance violates state statutes, the Gift Clause of the Arizona Constitution, and prior court orders finding such post-deadline approvals unlawful. This case epitomizes Arizona's broader regulatory capture problem, where 25 of 26 social equity licenses ended up controlled by large corporations instead of intended beneficiaries, with some selling for as little as $35,000. Campbell, who chaired Proposition 207's legalization campaign, now faces allegations of orchestrating the very regulatory favoritism that undermines the law he helped pass. The governor's office dismissed the suit as "sour grapes," but the documented communications between Campbell and Trulieve's lobbyist suggest systematic coordination that transforms cannabis regulation from policy implementation into political patronage. (Arizona Capitol Times)
Arkansas successfully enforced its hemp-derived THC ban after the 8th Circuit Court reversed a district judge's injunction in June, with state regulators warning permit holders that continued sales violate the law and demanding product removal from shelves. Alabama Governor Kay Ivey signed legislation banning smokable hemp products with a "six-month no-man's-land" enforcement gap between the July 2025 effective date and January 2026 licensing provisions, while Texas's similar ban remains stalled by Democratic legislators' walkout protest. The coordinated Southern crackdown reveals a strategic pattern where hemp industry legal challenges initially succeed at district court level but fail on appeal, with Attorney General Tim Griffin calling Arkansas's court victory "a win for common sense and the rule of law." Industry coalitions preparing litigation strategies face the reality that federal courts increasingly defer to state authority over hemp regulation, suggesting the 2018 Farm Bill's permissive framework won't protect synthetic THC products from state-level prohibition. (Dallas Observer)
A large-scale study funded by the National Science Foundation and National Institutes of Health found that cannabis users aged 44-81 demonstrated "superior performance across multiple cognitive domains" and brain network patterns "typically associated with younger brains" among 37,929 UK participants. The research published in Nature Portfolio suggests cannabis use "may be associated with a deceleration of neural aging processes" and preservation of cognitive function, with older adults representing the fastest-growing cannabis user demographic. The findings directly contradict decades of prohibitionist arguments about cognitive impairment, joining recent federally supported research showing cannabis doesn't trigger psychosis symptoms and may improve working memory in various populations. The study's federal funding and massive scale provide ammunition for medical cannabis advocates while undermining traditional opposition arguments that rely on outdated "reefer madness" cognitive decline claims. For policymakers weighing rescheduling decisions, the research offers scientific cover for supporting cannabis access among older constituencies who increasingly view marijuana as medicine rather than recreation. (Marijuana Moment)
Bologna-based Enecta saw its main e-commerce site vanish for two months without warning after Italy's Ministry of Health alleged a pet product contained THC, despite lab tests confirming zero THC content and the company never receiving formal notice of the decree. The takedown wiped out €150,000-€200,000 in revenue, destroyed search rankings, and cut traffic by over half, illustrating how arbitrary enforcement can devastate compliant businesses overnight. Prime Minister Giorgia Meloni's "Security Decree" classified industrial hemp flowers and non-psychoactive cannabinoids as narcotics regardless of THC content, directly contradicting EU law that permits free movement of hemp products under 0.3% THC. This creates a dangerous precedent where member states can unilaterally override European Court of Justice rulings and European Commission guidance recognizing CBD as non-narcotic and suitable for cosmetics and food supplements. The broader crackdown threatens a €2 billion sector supporting 30,000 jobs, with regional agriculture councils, legal scholars, and EU officials launching constitutional appeals and complaints. Italy's actions signal how populist politics can weaponize cannabis regulation to undermine established legal frameworks, creating investment uncertainty across European hemp markets where compliance offers no protection against ideological enforcement. (Hemp Today)
If you could add one new resource to Policy, Decoded or your toolkit, which would you choose?
- Daily Insider Briefings – rapid, members-only updates with strategic forecasts and next steps.
- Rapid Response War Room – 48-hour turnaround on urgent regulator or policy issues.
- Market Entry Scorecard – state-by-state risk and opportunity ranking.
- Crisis Playbooks – pre-written response templates for deficiency notices, enforcement actions, or PR hits.
- Bill & Regulation Tracker – live dashboard updated weekly with state and federal developments.
The deeper pattern behind today’s moves — and why it matters next.
🧾 Context: State treasuries thought they'd struck gold when cannabis taxes started outpacing alcohol revenue, but they built their budgets on a house of cards. California's cannabis revenue has cratered 30% from its 2021 peak while Colorado just watched $56.9 million vanish from school construction funds. The cruel irony? The same communities that bore the brunt of prohibition enforcement now shoulder the heaviest tax burden through regressive excise structures. ITEP's research cuts through the political theater to expose a fundamental design flaw: states betting on price-dependent revenue models are watching their windfalls evaporate as cannabis inevitably commoditizes. Meanwhile, only 27% of operators turned a profit in 2024, largely because federal 280E restrictions create effective tax rates of 70-80% that would bankrupt any other industry.
🔎 What It Signals: The systematic failure of cannabis tax policy across mature markets reveals how states designed systems assuming perpetual high pricing, creating automatic tax cuts precisely when fiscal pressure mounts. It's like building a bridge that gets weaker under heavy loads. California abandoned cultivation taxes then immediately hiked excise rates in a desperate revenue grab. New York threw in the towel on its byzantine potency tax after it created 45-day collection delays and drove operators to near-bankruptcy. Alaska's $50-per-ounce weight tax provides stability but generates such political heat that legislators are scrambling to cut rates. The federal overlay makes everything worse: 20 states have decoupled from 280E while others maintain punitive double taxation. This patchwork creates competitive distortions that already drive massive cross-border commerce, with Wisconsin residents dropping $36 million annually in Illinois dispensaries purely for tax arbitrage.
🧠 THC Group Take: Smart money recognizes this chaos as opportunity dressed up as crisis. Operators positioned in weight-based tax jurisdictions gain structural advantages because their burden stays predictable while competitors in ad valorem states face automatic margin compression during price wars. Schedule III rescheduling could eliminate $2.3 billion in federal excess taxes, fundamentally reframing state tax competitiveness. Suddenly, high-tax states with stable frameworks become more attractive than low-tax states with volatile structures. The sophisticated play involves three moves: first, prioritize markets where tax policy survives commoditization rather than chasing today's lowest rates. Second, exploit border positioning before interstate commerce eliminates current arbitrage opportunities. Third, implement advanced tax optimization including vertical integration for COGS maximization and strategic federal deferrals where penalties beat borrowing costs. Companies like Green Thumb paying more in taxes than generating operating cash flow illustrate the unsustainable status quo. Twenty state decoupling laws preview the post-rescheduling landscape where federal normalization rewards operators who built resilient unit economics under punitive frameworks. The winners will master multi-jurisdictional tax strategy while the laggards get crushed by their own governments' fiscal desperation.
From the hearing room to the comment section — we’re watching it all.
🎨 Creative joint rolling has evolved from party tricks into sculptural art, with artists spending days crafting "smokeable architecture" using colored papers, dowels, and custom 3D-printed molds. While MSOs chase scale and compliance costs, cultural innovators build luxury experiences one handcrafted piece at a time. (High Times)
🎯 Texas Republican DA Sarah Stogner livestreamed herself smoking weed to protest THC bans, crossing state lines from New Mexico with cannabis then lighting up outside her Ward County home while targeting Lieutenant Governor Dan Patrick. Bold prosecutorial immunity flex or career suicide? (Newsweek)